Immunology company argenx SE (Euronext Brussels:ARGX) (Nasdaq:ARGX) announced on Thursday that it has received approval from the European Commission for subcutaneous injectable VYVGART (efgartigimod alfa) as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
The EC previously approved VYVGART for intravenous (IV) use in August 2022.
This latest decision follows a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) and was based on positive results from the Phase 3 ADAPT-SC study.
The approval applies to all 27 European Union Member States plus Iceland, Norway and Liechtenstein.
VYVGART SC, a subcutaneous injectable formulation of efgartigimod alfa, incorporates Halozyme's ENHANZE drug delivery technology to facilitate SC injection delivery of biologics. By binding to the neonatal Fc receptor (FcRn), VYVGART leads to a reduction in circulating IgG autoantibodies.
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Avacta Group partners with Tempus to enhance AI-driven oncology drug development
PharmaLogic opens new radiopharmaceutical facility in Salt Lake City
Astellas Pharma's VYLOY receives US FDA approval
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
SHINE Technologies collaboration could result in new kidney and prostate cancer treatments
Elysium Health launches VISION for visual performance and eye health
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
Innovent Biologic meets primary endpoint in picankibart phase 2 study